Rubius Therapeutics Inc (RUBY)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

399 BINNEY STREET, SUITE 300 CAMBRIDGE, MA 02139

Rubius Therapeutics, Inc. operates as a bio-technology company. The Company develops cellular therapies for the treatment of auto-immune, metabolic, and other diseases. Rubius Therapeutics serves clients in the State of Massachusetts.

Data based on most recent fiscal year report
Market Cap678.3 Million Shares Outstanding79.8 Million Avg Volume412.377 Thousand
1-Yr BETA vs S&P TR0.572 Current Ratio20.72 Quick Ratio20.72
View SEC Filings from RUBY instead.

View recent insider trading info

Funds Holding RUBY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RUBY BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

15 Thousand total shares from 3 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PRENER ANNE

  • Director
0 2020-04-01 2

EPSTEIN DAVID R

  • Director
4,815,453 2020-03-17 3

POMERANTZ ROGER CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-02-21 0

ROSENBLATT MICHAEL

  • Director
7,882 2020-02-11 1

OH ANDREW M. CHIEF FINANCIAL OFFICER

  • Officer
0 2020-01-31 1

CAGNONI PABLO J CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-01-31 1

COUGHLIN CHRISTINA M. CHIEF MEDICAL OFFICER

  • Officer
0 2020-01-31 2

TURKA LAURENCE A. CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-01-31 2

SOHN CATHERINE A.

  • Director
1,000 2020-01-17 1

HOLLES NATALIE C. PRESIDENT AND COO

  • Officer
0 2020-01-15 0

CARPENTER CHRISTOPHER L. CHIEF MEDICAL OFFICER

  • Officer
34,843 2019-12-16 4

KESON-BROOKES MAIKEN CLO & CORP. SECRETARY

  • Officer
0 2019-11-29 2

LANGER ROBERT

  • Director
0 2019-10-14 4

NISSEN TORBEN STRAIGHT PRESIDENT

  • Officer
2,052,450 2019-07-24 2

AFEYAN NOUBAR

  • Director
  • 10% Owner
0 2019-06-27 1

SYMONDS JONATHAN

  • Director
0 2019-05-23 1

CUSS FRANCIS M

  • Director
0 2019-05-23 1

FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

FLAGSHIP VENTURELABS IV, LLC

FLAGSHIP VENTURES FUND IV, L.P.

FLAGSHIP VENTURES FUND IV-RX, L.P.

FLAGSHIP VENTURES FUND V, L.P.

FLAGSHIP V VENTURELABS RX FUND, L.P.

FLAGSHIP VENTURES OPPORTUNITIES FUND I, L.P.

AFEYAN NOUBAR

KANIA EDWIN M JR

  • Director
  • 10% Owner
56,266,265 2018-07-20 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

EPSTEIN DAVID R - Director

2020-03-17 P 5,000 $3.76 a 4,815,453 4,815,453.00 direct

EPSTEIN DAVID R - Director

2020-03-13 P 5,000 $3.82 a 4,805,453 4,810,453.00 direct

EPSTEIN DAVID R - Director

2020-03-13 P 5,000 $4.00 a 4,810,453 4,810,453.00 direct

Elevate your investments